What question did this study set out to answer?

This study aims to characterize ruxolitinib pharmacokinetics in real-world clinical practice and investigate its exposure-toxicity relationship.

June 27, 2026Open Access

Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

View Full Paper

Ask AI

Bookmark

Authors

Prospective observational study investigates ruxolitinib exposure in adults, linking it to toxicity risks.

This study aims to characterize ruxolitinib pharmacokinetics in real-world clinical practice and investigate its exposure-toxicity relationship.
Analyzed 221 ruxolitinib concentrations from 77 adult patients across multiple centers in Switzerland.
Performed population pharmacokinetic analysis using MonolixSuite® 2024R1.
Conducted model-based simulations to assess trough concentration and area under the curve.
Ruxolitinib clearance showed 45% between-subject variability.
Cytochrome inhibitors reduced ruxolitinib clearance by 39%, with increased median Cmin and AUC24 by 2.9- and 1.7-fold at 10 mg twice daily respectively.
Higher ruxolitinib exposure was associated with increased toxicity (Cmin and AUC24, P≈0.02-0.03).

Tachet et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark